MindMaze Therapeutics Unveils MindMotion Lite for Enhanced Home Neurorehabilitation

MindMaze Therapeutics has announced the launch of MindMotion Lite by the end of 2026. This tablet-based tool aims to expand home access to neurorehabilitation, offering a comprehensive range of neurotherapeutic activities. The solution is designed to make intensive therapy more accessible for patients returning home from clinical settings.

MindMotion Lite retains full-body rehabilitation capabilities and supports teleconsultation and remote management, facilitating healthcare professionals in providing continuing care. The American Heart Association guidelines emphasize the importance of post-stroke neurotherapy, which MindMotion Lite seeks to address, bridging the care gap for patients.

This initiative complements MindMaze's current suite of solutions and is expected to streamline distribution and reduce deployment costs compared to its predecessor, MindMotion GO. The company plans to showcase MindMotion Lite at upcoming conferences, with further details on availability to follow.